Bimodal Therapeutic Agents against Glioblastoma, one of the most Lethal Cancer
release_rev_325ada5e-9fb7-4b7d-a460-a3cfa242d7ae
by
Hugo Eduardo Cerecetto, Marcos Couto, Catalina Alamón, Susana Nievas, María Alejandra Dagrosa, Francesc Teixidor, Pablo Cabral, Clara Viñas, Marina Perona
Abstract
About 95% of people diagnosed with glioblastoma die within five years. Glioblastoma is the most aggressive central nervous system tumour. It is necessary to make progress in the glioblastoma treatment so that advanced chemotherapy drugs or radiation therapy or, ideally, two-in-one hybrid systems should be implemented. Tyrosine kinase receptors-inhibitors and boron neutron capture therapy (BNCT), together, could provide a therapeutic strategy. In this work, sunitinib decorated-carborane hybrids were prepared and biologically evaluated identifying excellent antitumoral- and BNCT-agents. One of the selected hybrids was studied against glioma-cells finding that it was 4-times more cytotoxic than sunitinib and 1.7-times more effective than 10B- boronophenylalanine fructose complex when the cells were irradiated with neutrons.
In text/plain
format
access all versions, variants, and formats of this works (eg, pre-prints)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar
This is a specific, static metadata record, not necessarily linked to any current entity in the catalog.